Table 6 Comorbidities in patients with refractory and non-refractory MG and age- and sex-matched controls
From: A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis
Baseline (pre-index to index) period | Follow-up (post-index) period | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Refractory MG | Non-refractory MG | Refractory vs non-refractory | Controlsa | Refractory MG vs controls | Refractory MG | Non-refractory MG | Refractory vs non-refractory | Controlsa | Refractory MG vs controls | |
(N = 66) | (N = 1083) | P-value | (N = 252) | P-value | (N = 66) | (N = 1083) | P-value | (N = 252) | P-value | |
Comorbidity | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||
Myocardial infarction | 3 (4.6) | 80 (7.4) | 0.39 | 10 (4.0) | 0.83 | 9 (13.6) | 160 (14.8) | 0.80 | 21 (8.3) | 0.19 |
Congestive heart failure | 1 (1.5) | 43 (4.0) | 0.31 | 8 (3.2) | 0.47 | 13 (19.7) | 139 (12.8) | 0.11 | 25 (9.9) | 0.03 |
Peripheral vascular disease | 3 (4.6) | 58 (5.4) | 0.78 | 6 (2.4) | 0.35 | 5 (7.6) | 74 (6.8) | 0.82 | 14 (5.6) | 0.54 |
Cerebrovascular disease | 2 (3.0) | 104 (9.6) | 0.07 | 12 (4.8) | 0.54 | 5 (7.6) | 87 (8.0) | 0.89 | 20 (7.9) | 0.92 |
Dementia | 0 (0.0) | 13 (1.2) | 0.37 | 2 (0.8) | 0.47 | 5 (7.6) | 65 (6.0) | 0.60 | 15 (6.0) | 0.63 |
COPD | 6 (9.1) | 123 (11.4) | 0.57 | 16 (6.4) | 0.43 | 13 (19.7) | 223 (20.6) | 0.86 | 35 (13.9) | 0.24 |
Rheumatologic disease | 3 (4.6) | 34 (3.1) | 0.53 | 3 (1.2) | 0.07 | 5 (7.6) | 53 (4.9) | 0.33 | 9 (3.6) | 0.16 |
Peptic ulcer disease | 2 (3.0) | 48 (4.4) | 0.59 | 5 (2.0) | 0.61 | 0 (0.0) | 9 (0.8) | 0.46 | 4 (1.6) | 0.30 |
Liver disease, mild | 2 (3.0) | 14 (1.3) | 0.24 | 0 (0.0) | < 0.01 | 4 (6.1) | 33 (3.1) | 0.18 | 7 (2.8) | 0.19 |
Liver disease, moderate–severe | 0 (0.0) | 3 (0.3) | 0.67 | 0 (0.0) | NC | 1 (1.5) | 12 (1.1) | 0.76 | 3 (1.2) | 0.83 |
Hemiplegia or paraplegia | 1 (1.5) | 13 (1.2) | 0.82 | 1 (0.4) | 0.31 | 1 (1.5) | 21 (1.9) | 0.81 | 3 (1.2) | 0.83 |
Renal disease | 8 (12.1) | 120 (11.1) | 0.79 | 20 (7.9) | 0.29 | 22 (33.3) | 243 (22.4) | 0.04 | 51 (20.2) | 0.02 |
Malignancy | 6 (9.1) | 93 (8.6) | 0.89 | 22 (8.7) | 0.93 | 14 (21.2) | 179 (16.5) | 0.32 | 41 (16.3) | 0.34 |
Metastatic solid tumor | 1 (1.5) | 13 (1.2) | 0.82 | 4 (1.6) | 0.97 | 3 (4.6) | 59 (5.5) | 0.75 | 14 (5.6) | 0.75 |
HIV/AIDS | 0 (0.0) | 0 (0.0) | NC | 0 (0.0) | NC | 0 (0.0) | 1 (0.1) | 0.80 | 0 (0.0) | NC |
Hypertension | 22 (33.3) | 415 (38.3) | 0.42 | 71 (28.2) | 0.41 | 16 (24.2) | 156 (14.4) | 0.03 | 32 (12.7) | 0.02 |
Ankylosing spondylitis | 9 (13.6) | 136 (12.6) | 0.80 | 27 (10.7) | 0.50 | 5 (7.6) | 83 (7.7) | 0.98 | 12 (4.8) | 0.37 |
Psoriasis | 4 (6.1) | 46 (4.3) | 0.48 | 4 (1.6) | 0.04 | 4 (6.1) | 21 (1.9) | 0.03 | 3 (1.2) | 0.02 |
Psoriatic arthritis | 2 (3.0) | 1 (0.1) | < 0.0001 | 0 (0.0) | < 0.01 | 2 (3.0) | 4 (0.4) | < 0.01 | 0 (0.0) | < 0.01 |
Crohn's disease | 0 (0.0) | 7 (0.7) | 0.51 | 1 (0.4) | 0.61 | 0 (0.0) | 4 (0.4) | 0.62 | 1 (0.4) | 0.61 |
Ulcerative colitis | 0 (0.0) | 10 (0.9) | 0.43 | 0 (0.0) | NC | 0 (0.0) | 12 (1.1) | 0.39 | 0 (0.0) | NC |
Systemic lupus erythematosus | 1 (1.5) | 6 (0.6) | 0.33 | 1 (0.4) | 0.31 | 1 (1.5) | 4 (0.4) | 0.17 | 0 (0.0) | 0.05 |
Lupus nephritis | 0 (0.0) | 0 (0.0) | NC | 0 (0.0) | NC | 0 (0.0) | 0 (0.0) | NC | 0 (0.0) | NC |
Diabetes without chronic complications | 8 (12.1) | 146 (13.5) | 0.75 | 23 (9.1) | 0.47 | 18 (27.3) | 213 (19.7) | 0.13 | 35 (13.9) | 0.01 |
Diabetes with chronic complications | 3 (4.6) | 40 (3.7) | 0.72 | 6 (2.4) | 0.35 | 6 (9.1) | 50 (4.6) | 0.10 | 5 (2.0) | < 0.01 |